Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL614697 Target Snapshot

MDA-MB-435 · CELL-LINE · Homo sapiens

34,101Compounds
1,731Assays
30Approved Drugs
2,729.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats MDA-MB-435 as ChEMBL target CHEMBL614697. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
MDA-MB-435
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL614697
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether MDA-MB-435 still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMDA-MB-435
UniProt AccessionN/A

MDA-MB-435

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as MDA-MB-435.

Review nameMDA-MB-435
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

30
Approved
3
Phase III
8
Phase II
3
Phase I
Assay Mix

Activity Type Distribution

IC502,670.0
KI28.0
EC5030.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL56157 9.82 IC50 0.15 Preclinical
CHEMBL5435771 9.7 IC50 0.2 Preclinical
CHEMBL3633920 9.7 IC50 0.2 Preclinical
CHEMBL428647 9.7 IC50 0.2 Approved
CHEMBL6966 9.6 IC50 0.25 Approved
CHEMBL159 9.57 IC50 0.27 Approved
CHEMBL90555 9.54 IC50 0.29 Approved
CHEMBL4061080 9.52 IC50 0.3 Preclinical
CHEMBL3633919 9.52 IC50 0.3 Preclinical
CHEMBL58 9.46 IC50 0.35 Approved
Distribution

pChEMBL Value Distribution

338
5.0
317
5.5
260
6.0
183
6.5
148
7.0
137
7.5
80
8.0
33
8.5
28
9.0
14
9.5
pChEMBL
Approved Drugs

Approved Drugs

PALBOCICLIB
CHEMBL189963
Approved 2015
LAPATINIB
CHEMBL554
Approved 2007
SUNITINIB
CHEMBL535
Approved 2006
ERLOTINIB
CHEMBL553
Approved 2004
EPIRUBICIN
CHEMBL417
Approved 1999
TOPOTECAN
CHEMBL84
Approved 1996
DOCETAXEL
CHEMBL3545252
Approved 1995
PACLITAXEL
CHEMBL428647
Approved 1992
MITOXANTRONE
CHEMBL58
Approved 1987
DIGITOXIN
CHEMBL254219
Approved 1982
VERAPAMIL
CHEMBL6966
Approved 1981
DAUNORUBICIN
CHEMBL178
Approved 1979
TAMOXIFEN
CHEMBL83
Approved 1977
DIGOXIN
CHEMBL1751
Approved 1975
DOXORUBICIN
CHEMBL53463
Approved 1974
VINBLASTINE
CHEMBL159
Approved 1965
VINCRISTINE
CHEMBL90555
Approved 1963
FLUOROURACIL
CHEMBL185
Approved 1962
COLCHICINE
CHEMBL107
Approved 1961
Assay Landscape

Assay Landscape

1,731
Total Assays
1,603
Tested Compounds
4
Assay Types
Functional — 1,685 assays, 1,603 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1,594 1,588 6.0
organism-based format 90 15 7.2
assay format 1 0
ADME — 39 assays, 3 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 39 3 5.2
Toxicity — 5 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 5 0
Unassigned — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine